The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the industrialization and translation of extracellular vesicles (EVs) for use in regenerative medicine. EVs are membrane-enclosed carriers of bioactive substances that play a role in intercellular communication. This funding opportunity aims to support the development of novel EV-based therapeutic platforms for tissue and organ repair in regenerative medicine. The focus is on the production, manufacturing, and use of native or engineered EVs as therapeutics. The goal is to address challenges in the field, such as large-scale production and manufacturing of EVs for therapeutic use. The funding opportunity is open to small business concerns and offers both Phase I and Phase II grants. Phase I applications should focus on feasibility and therapeutic applications, while Phase II applications should optimize and scale-up technology platforms. The validation of therapeutic benefits is required for Phase II applications. The development of IND enabling therapeutic platforms that can work towards regulatory approval and commercialization is prioritized. Applications must include project milestones and should align with the goals of the funding opportunity. The application due dates are June 6th of each year from 2023 to 2025. For more information, visit the solicitation agency URL: link.